ARS Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

ARS Pharmaceuticals

13/11/2024 14:17

* ARS Pharmaceuticals Inc  SPRY.OQ  reported a quarterly
adjusted
loss of 20 cents​​ per share for the quarter ended September 30,
lower than the same quarter last year, when the company reported
EPS of -16 cents.  The mean expectation of four analysts for the
quarter was for a loss of 15 cents per share. Wall Street
expected results to range from -19 cents to -6 cents per share.
    * Revenue was $2.07 million​; analysts expected $575.00
thousand. 
    * ARS Pharmaceuticals Inc's reported EPS for the quarter was
a
loss of 20 cents​.
    * The company reported a quarterly loss of $19.13 million.
    * ARS Pharmaceuticals Inc shares had risen by 14.6% this
quarter and gained 203.1% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 16.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for ARS
Pharmaceuticals Inc is $25.00 
This summary was machine generated from LSEG data November 13 at
02:17 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.15          -0.20          Missed
 Jun. 30 2024      -0.12          -0.13          Missed
 Mar. 31 2024      -0.11          -0.11          Met
 Dec. 31 2023      -0.14          -0.07          Beat